{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:01:42Z","timestamp":1771844502194,"version":"3.50.1"},"reference-count":112,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Light-chain (AL) amyloidosis is a rare and incurable disease, classified under the category of plasma cell neoplasms and other diseases with paraproteins in the 5th Edition of the World Health Organization classification of lymphoid tumors. This entity shares some similarities with multiple myeloma (MM), remarkably a bone marrow infiltration of clonal plasma cells. Moreover, one out of five newly diagnosed cases of AL amyloidosis (NDAL) also fulfills the current diagnostic criteria for MM. A multidisciplinary therapy approach should be established, in which hematological therapy plays a crucial role. Anti-clonal therapy is the basis of hematological therapy, in addition to supportive therapy and emerging anti-fibrils therapy. In recent years, advances in the anti-clonal therapy for MM have progressively transferred to carefully selected patients with systemic AL amyloidosis, significantly improving outcomes in this rapidly changing field. This review aims to critically analyze the comparative evolution and evidence-based approach of anti-clonal therapy in NDAL vs. MM since the introduction of bortezomib. Participation in clinical trials remains the first option to consider in daily clinical practice.<\/jats:p>","DOI":"10.3390\/life16020363","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:00:52Z","timestamp":1771840852000},"page":"363","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-1402","authenticated-orcid":false,"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Virgen de las Nieves, 18014 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA, 18012 Granada, Spain"},{"name":"CIBER Epidemiology and Public Health, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., Krsnik, I., G\u00f3mez-Bueno, M., Garcia-Pavia, P., Segovia-Cubero, J., Huerta, A., Salas, C., Silvestre, R., S\u00e1nchez, A., and Manso, M. (2023). AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor. Life, 13.","DOI":"10.3390\/life13071518"},{"key":"ref_3","unstructured":"Rezaei, N. (2024). Monoclonal Gammopathies. Comprehensive Hematology and Stem Cell Research, Elsevier. [1st ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., Paiva, B., Lahuerta, J.J., Mart\u00ednez L\u00f3pez, J., and Duarte, R.F. (2022). Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal. Cancers, 14.","DOI":"10.3390\/cancers14215247"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., S\u00e1nchez, M.J., G\u00f3mez-Rojas, S., Rodr\u00edguez-Barranco, M., Segura, G.P., Redondo-S\u00e1nchez, D., G\u00f3mez-Tarragona, G., Nicol\u00e1s, A.R., Ruiz-Cabello, F., and Jim\u00e9nez, P. (2023). Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061071"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ajh.24389","article-title":"Early mortality in multiple myeloma: The time-dependent impact of comorbidity. A population-based study in 621 real-life patients","volume":"91","author":"Sainz","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., Lecumberri, R., Cibeira, M.T., Gonz\u00e1lez-Calle, V., Alonso, R., Domingo-Gonz\u00e1lez, A., Landete, E., Encinas, C., I\u00f1igo, B., and Blanchard, M.J. (2024). A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis. Cancers, 16.","DOI":"10.20944\/preprints202404.0717.v1"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Al-Anazi, K.A. (2019). Epidemiology of Multiple Myeloma. Update on Multiple Myeloma, Intech.","DOI":"10.5772\/intechopen.72220"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R. (2025). Epidemiology of systemic light-chain (AL) amyloidosis. Lymphatics, 3.","DOI":"10.20944\/preprints202505.1450.v1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: Grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.2024024623","article-title":"Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population","volume":"144","author":"Muchtar","year":"2024","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials","volume":"100","author":"Filippatos","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2024-202995","article-title":"Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis","volume":"144","author":"Lasa","year":"2024","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sarubbi, C., Abowali, H., Varga, C., and Landau, H. (2024). Treatment of AL amyloidosis in the era of novel immune and cellular therapies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1425521"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan, M., Osman, W., Krisnagopal, A., Parry, M., Davis, M., and Chu, C.H. (2025). Integrated specialty care for amyloidosis: A scoping review using the Consolidated Framework for Implementation Research. BMC Health Serv. Res., 25.","DOI":"10.1186\/s12913-025-12520-3"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13506129.2025.2463678","article-title":"Supportive care for systemic amyloidosis: International Society of Amyloidosis (ISA) expert panel guidelines","volume":"32","author":"Muchtar","year":"2025","journal-title":"Amyloid"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6004\/jnccn.2022.7092","article-title":"Individualized Approach to Management of Light Chain Amyloidosis","volume":"21","author":"Palladini","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101207","DOI":"10.1016\/j.blre.2024.101207","article-title":"Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis","volume":"66","author":"Wang","year":"2024","journal-title":"Blood Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Emdin, M., Vergaro, G., Aimo, A., and Fontana, M. (2024). A Brief history of amyloidosis. Cardiac Amyloidosis, Springer.","DOI":"10.1007\/978-3-031-51757-0"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with sarcolysin in neoplastic diseases","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archinte.1961.03620030032004","article-title":"\u201cPrimary\u201d Systemic Amyloidosis and Myeloma Discussion of Relationship and Review of 81 Cases","volume":"107","author":"Kyle","year":"1961","journal-title":"Arch. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0140-6736(72)93014-0","article-title":"Treatment of \u201cprimary\u201d renal amyloidosis with melphalan","volume":"300","author":"Jones","year":"1972","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","article-title":"Amyloidosis: Review of 236 cases","volume":"54","author":"Kyle","year":"1975","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"HemaSphere"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1182\/blood-2018-04-845396","article-title":"Treatment of AL amyloidosis with bendamustine: A study of 122 patients","volume":"132","author":"Milani","year":"2018","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e936\u2013940","DOI":"10.1016\/S2352-3026(23)00175-8","article-title":"Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies","volume":"10","author":"Chakraborty","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","article-title":"Immunomodulatory drugs in AL amyloidosis","volume":"99","author":"Jelinek","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-143106","article-title":"Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of NewlyDiagnosed AL Amyloidosis: A Systematic Review","volume":"136","author":"Javed","year":"2020","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.hoc.2020.08.005","article-title":"Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis","volume":"34","author":"Godara","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_33","first-page":"22","article-title":"Antibody drug conjugates for the treatment of multiple myeloma","volume":"98","author":"Leong","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood.2021014613","article-title":"Daratumumab in AL amyloidosis","volume":"140","author":"Wechalekar","year":"2022","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2024027962","article-title":"Isatuximab for relapsed and\/or refractory AL amyloidosis: Results of a prospective phase 2 trial (SWOG S1702)","volume":"146","author":"Parker","year":"2025","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/ajh.27684","article-title":"Elotuzumab in Combination with Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients with Relapsed\/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement","volume":"100","author":"Dittrich","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood.2025030526","article-title":"BCMA: BeCoMing a new hope for AL amyloidosis","volume":"146","author":"Kastritis","year":"2025","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjh.19960","article-title":"Update on B-cell maturation antigen-directed therapies in AL amyloidosis","volume":"206","author":"Jamroziak","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood-2021-151365","article-title":"Belantamab Mafadotin in Patients with Relapsed\/Refractory AL Amyloidosis with Myeloma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jha2.772","article-title":"First report of teclistamab in a patient with relapsed AL amyloidosis and multiple mieloma","volume":"4","author":"Leung","year":"2023","journal-title":"EJHaem"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2025028383","article-title":"Safety and efficacy of elranatamab in patients with daratumumab relapsed and\/or refractory immunoglobulin light-chain amyloidosis","volume":"146","author":"Vianna","year":"2025","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2025-692","article-title":"Phase 1\/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lewis, E., and Jimenez-Zepeda, V.H. (2025). BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32080418"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and Safety of Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis","volume":"43","author":"Lebel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2025.43.16_suppl.7508","article-title":"Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R\/R light chain (AL) amyloidosis, NXC-201","volume":"43","author":"Landau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/bloodadvances.2025017488","article-title":"AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy","volume":"10","author":"Tan","year":"2025","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ejh.14293","article-title":"Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma and concurrent light chain amyloidosis","volume":"113","author":"Goel","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2025-2181","article-title":"The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis","volume":"146","author":"Rees","year":"2025","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e003783","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CAR-T therapy in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Cibeira","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"Vega","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple mieloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Huang, X., Wang, Q., Chen, W., Zeng, C., Chen, Z., Gong, D., Zhang, H., and Liu, Z. (2014). Induction therapy with bortezomib andexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: A randomized controlled trial. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-2"},{"key":"ref_55","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients with Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics","volume":"25","author":"Oriol","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3324\/haematol.2018.213900","article-title":"Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: Results of the multicenter HOVON 104 trial","volume":"104","author":"Minnema","year":"2019","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As InductionTreatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2019.08.016","article-title":"Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis","volume":"26","author":"Landau","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.13243","article-title":"A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation","volume":"169","author":"Girnius","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II Trial of Combination Therapy with Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients with Newly Diagnosed Myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib Induction and Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65\/GMMG-HD4 Trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"Schlag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide Compared with Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","article-title":"Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM","volume":"127","author":"Mateos","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3026(25)00143-7","article-title":"Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): A phase 3, open-label, multicentre, randomised clinical trial","volume":"12","author":"Mateos","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","article-title":"Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial","volume":"145","author":"Shen","year":"2022","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2141.2009.07981.x","article-title":"Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma","volume":"148","author":"Bensinger","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bjh.14920","article-title":"Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial","volume":"179","author":"Einsele","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000495338","article-title":"Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial","volume":"141","author":"Tanaka","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood.V122.21.3193.3193","article-title":"Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) with Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy","volume":"122","author":"Berdeja","year":"2013","journal-title":"Blood"},{"key":"ref_81","first-page":"1096","article-title":"Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish\/PETHEMA trial","volume":"100","author":"Mateos","year":"2013","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA\/GEM trial","volume":"31","author":"Oriol","year":"2017","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjh.13582","article-title":"Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up","volume":"171","author":"Ludwig","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Oriol","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/blood-2024-209626","article-title":"A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+\/\u2212 Dara Maintenance): SWOG S2209","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-023-00816-8","article-title":"Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study","volume":"13","author":"Saj","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2017.35.15_suppl.8002","article-title":"An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma","volume":"35","author":"Laubach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S2352-3026(23)00366-6","article-title":"Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): Results from a randomised, phase 3 trial","volume":"11","author":"Mai","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2023-173476","article-title":"Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients\u2014A Trial By Asian Myeloma Network","volume":"142","author":"Nagarajan","year":"2023","journal-title":"Blood"},{"key":"ref_94","first-page":"2355","article-title":"Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: A prospective phase II study","volume":"109","author":"Shen","year":"2024","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1182\/blood-2023-178533","article-title":"Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)","volume":"142","author":"Beksac","year":"2023","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1182\/blood-2023-181953","article-title":"Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius","volume":"142","author":"Rosenzweig","year":"2023","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/bloodadvances.2023012539","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16","volume":"8","author":"Mollee","year":"2024","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3309.1","DOI":"10.1182\/blood-2024-208227","article-title":"A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis","volume":"144","author":"Hagen","year":"2024","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e874-883","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): Health-related quality of life outcomes of a randomised, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): A multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2024-203527","article-title":"Defining a New \u201cMayo Stage IIIc\u201d Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System","volume":"144","author":"Khwaja","year":"2024","journal-title":"Blood"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/2\/363\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:13:56Z","timestamp":1771841636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/2\/363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["life16020363"],"URL":"https:\/\/doi.org\/10.3390\/life16020363","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}